Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
22 studies found for:    17237035 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated
Has Results
Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer
Condition: Non-Small-Cell Lung Cancer
Intervention: Drug: Pioglitazone
2 Terminated
Has Results
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor Infiltrating Lymphocytes;   Drug: IL-15
3 Terminated
Has Results
Sunitinib to Treat Recurrent Brain Cancer
Conditions: Glioblastoma Multiforme;   Malignant Gliomas;   Anaplastic Gliomas
Intervention: Drug: Sutent (sunitinib)
4 Suspended Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin;   Drug: Rituximab;   Drug: Bendamustine
5 Recruiting Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]
Condition: Squamous Cell Carcinoma of the Penis
Intervention: Procedure: MRI-PET
6 Recruiting Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cylcophosphamide;   Genetic: 41BB Selected Tumor Infiltrating Lymphocytes
7 Active, not recruiting Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease
Conditions: Squamous Cell Lung Cancer;   Lung Cancer;   Pulmonary Disease
Intervention: Device: Optical Frequency Domain Imaging (OFDI) System
8 Terminated
Has Results
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Drug: MART-1 Reactive CD8+ PBL
9 Active, not recruiting Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
Condition: Metastatic Breast Cancer
Intervention: Drug: Avastin + mFOLFOX6
10 Unknown  Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib;   Procedure: FDG-/FLT-PET
11 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young Tumor Infiltrating Lymphocytes (young TIL)
12 Terminated
Has Results
TRC105 for Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Intervention: Drug: TRC105
13 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
14 Completed Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
Conditions: Carcinoma, Squamous;   Head and Neck Cancer;   Oral Cancer;   Laryngeal Cancer;   Pharyngeal Cancer
Interventions: Drug: Bortezomib (Velcade, PS-341);   Drug: Cetuximab;   Drug: Cisplatin;   Procedure: Radiation Therapy
15 Recruiting Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Condition: Leukemia, Hairy Cell
Interventions: Drug: moxetumomab pasudotox;   Drug: IV Bag Protectant for Moxetumomab pasudotox
16 Completed
Has Results
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin;   Biological: Tumor Infiltrating Lymphocytes
17 Recruiting Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
18 Completed
Has Results
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
Conditions: NSCLC;   Solid Tumors
Interventions: Drug: YM155;   Drug: Carboplatin;   Drug: Paclitaxel
19 Terminated 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
Condition: Lymphoma
Interventions: Procedure: Biopsy;   Radiation: Fluordeoxyglucose F 18;   Other: [3'-deoxy-3'-[F-18] fluorothymidine;   Procedure: computed tomography;   Procedure: fine-needle aspiration
20 Completed
Has Results
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
Conditions: Skin Cancer;   Melanoma;   Metastatic Melanoma
Interventions: Biological: Aldesleukin;   Biological: CD8 enriched Young TIL

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years